Adenoviral vectors infect B lymphocytes in vivo.

ABSTRACT: B cells are the antibody-producing arm of the adaptive immune system and play a critical role in controlling pathogens. Several groups have now demonstrated the feasibility of using engineered B cells as a therapy, including infectious disease control and gene therapy of serum deficiencies. These studies have largely utilized ex vivo modification of the cells. Direct in vivo engineering would be of utility to the field, particularly in infectious disease control where the infrastructure needs of ex vivo cell modification would make a broad vaccination campaign highly challenging. In this study we demonstrate that engineered adenoviral vectors are capable of efficiently transducing murine and human primary B cells both ex vivo and in vivo. We found that unmodified human adenovirus C5 was ca

SUBMITTER: Rice-Boucher PJ 

PROVIDER: S-EPMC10492023 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature